BR112020005841A8 - Peptídeo coagonista do receptor de gcg/glp-1, composição, método para tratar um paciente de uma doença ou distúrbio metabólico, e, uso de um ou mais peptídeos coagonistas. - Google Patents

Peptídeo coagonista do receptor de gcg/glp-1, composição, método para tratar um paciente de uma doença ou distúrbio metabólico, e, uso de um ou mais peptídeos coagonistas.

Info

Publication number
BR112020005841A8
BR112020005841A8 BR112020005841A BR112020005841A BR112020005841A8 BR 112020005841 A8 BR112020005841 A8 BR 112020005841A8 BR 112020005841 A BR112020005841 A BR 112020005841A BR 112020005841 A BR112020005841 A BR 112020005841A BR 112020005841 A8 BR112020005841 A8 BR 112020005841A8
Authority
BR
Brazil
Prior art keywords
coagonist
glp
gcg
disorder
patient
Prior art date
Application number
BR112020005841A
Other languages
English (en)
Other versions
BR112020005841A2 (pt
Inventor
Palani Anandan
Deng Qiaolin
Huang Chunhui
Bianchi Elisabetta
Orvieto Federica
Zhu Yuping
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Publication of BR112020005841A2 publication Critical patent/BR112020005841A2/pt
Publication of BR112020005841A8 publication Critical patent/BR112020005841A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

São descritos coagonistas de ação prolongada dos receptores de glucagon e GLP-1.
BR112020005841A 2017-09-25 2018-09-21 Peptídeo coagonista do receptor de gcg/glp-1, composição, método para tratar um paciente de uma doença ou distúrbio metabólico, e, uso de um ou mais peptídeos coagonistas. BR112020005841A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762562674P 2017-09-25 2017-09-25
US62/562,674 2017-09-25
PCT/US2018/052124 WO2019060660A1 (en) 2017-09-25 2018-09-21 CO-AGONISTS WITH EXTENDED ACTION OF GLUCAGON AND GLP-1 RECEPTORS

Publications (2)

Publication Number Publication Date
BR112020005841A2 BR112020005841A2 (pt) 2020-11-17
BR112020005841A8 true BR112020005841A8 (pt) 2023-04-11

Family

ID=65810991

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020005841A BR112020005841A8 (pt) 2017-09-25 2018-09-21 Peptídeo coagonista do receptor de gcg/glp-1, composição, método para tratar um paciente de uma doença ou distúrbio metabólico, e, uso de um ou mais peptídeos coagonistas.

Country Status (11)

Country Link
US (1) US11566057B2 (pt)
EP (1) EP3700550A4 (pt)
JP (3) JP2020535138A (pt)
KR (1) KR102505628B1 (pt)
CN (1) CN111132690A (pt)
AU (1) AU2018338184B2 (pt)
BR (1) BR112020005841A8 (pt)
CA (2) CA3076496A1 (pt)
MA (1) MA50474A (pt)
MX (1) MX2020003217A (pt)
WO (1) WO2019060660A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3842060A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
EP3842449A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors
CN116710462A (zh) 2021-01-20 2023-09-05 维京治疗公司 用于治疗代谢病症和肝病的组合物和方法
KR20240043778A (ko) * 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
GB0308801D0 (en) * 2003-04-16 2003-05-21 Celltech R&D Ltd Chemical compounds
WO2006134340A2 (en) 2005-06-13 2006-12-21 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
KR20090119876A (ko) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
PA8830501A1 (es) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
BR112017008160A8 (pt) * 2014-10-24 2023-04-11 Merck Sharp & Dohme Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição
EP3377521A4 (en) * 2015-10-27 2019-05-01 Merck Sharp & Dohme Corp. LONG-ACTING CO AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
US20190175744A1 (en) 2016-03-18 2019-06-13 Merck Sharp & Dohme Corp. Insulin-incretin conjugates

Also Published As

Publication number Publication date
US11566057B2 (en) 2023-01-31
CA3076496A1 (en) 2019-03-28
BR112020005841A2 (pt) 2020-11-17
KR20200057059A (ko) 2020-05-25
JP2023071869A (ja) 2023-05-23
JP2023171744A (ja) 2023-12-05
RU2020114220A (ru) 2021-10-27
MX2020003217A (es) 2020-07-29
CA3220650A1 (en) 2019-03-28
RU2020114220A3 (pt) 2021-12-28
AU2018338184B2 (en) 2023-04-13
EP3700550A1 (en) 2020-09-02
AU2018338184A1 (en) 2020-03-12
US20200270325A1 (en) 2020-08-27
WO2019060660A1 (en) 2019-03-28
EP3700550A4 (en) 2022-02-23
CN111132690A (zh) 2020-05-08
KR102505628B1 (ko) 2023-03-02
JP2020535138A (ja) 2020-12-03
MA50474A (fr) 2020-09-02

Similar Documents

Publication Publication Date Title
BR112020005841A8 (pt) Peptídeo coagonista do receptor de gcg/glp-1, composição, método para tratar um paciente de uma doença ou distúrbio metabólico, e, uso de um ou mais peptídeos coagonistas.
CY1122539T1 (el) Αναλογα γλυκαγονης
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CY1121462T1 (el) Ακυλιωμενα αναλογα γλυκαγονης
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
EA201991345A1 (ru) Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip
PE20180449A1 (es) Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
BR112018012794A2 (pt) receptor de célula t, tcr que se liga a um complexo hla-a*02 sllmwitqc, fusão anti-cd3 de tcr, ácido nucléico, vetor de expressão, célula que ocorre e/ou purificada e/ou concebida de maneira não natural, célula, composição farmacêutica, método de tratamento de um indivíduo humano, formulação injetável para administração a um indivíduo humano, e método de produção de uma tcr
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
PH12017502052A1 (en) Substituted tetrahydroquinolinone compounds as ror gamma modulators
EA201991207A1 (ru) Новые агонисты tnfr и их применение
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
EA201590294A1 (ru) Аналоги глюкагона
CL2015003290A1 (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4).
CL2016002809A1 (es) Compuestos derivados de pirrol, piridina o piperidina sustituidos con heterociclos, moduladores del receptor acoplado a la proteína g 40 (gpr40); composición farmacéutica que los comprende; y su uso para el tratamiento de enfermedades como diabetes, retinopatía, neuropatía, aterosclerosis, obesidad e hipertensión.
EA201790254A1 (ru) Новые модуляторы рецептора glp-1
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112018069930A2 (pt) agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos
BR112017014994A2 (pt) formulação em pó nasal para o tratamento de hipoglicemia
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
AU2015278731B2 (en) Fused triterpene compounds and uses thereof
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
EA201692395A1 (ru) Новые соединения

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)